FDA Staff Criticizes Tobacco Product Application Review Process

Oct.31.2022
FDA Staff Criticizes Tobacco Product Application Review Process
FDA's Center for Tobacco Products is accused of lacking scientific independence in pre-market tobacco product applications review.

A commentary states that reviewers of Pre-Market Tobacco Product Applications (PMTA) at the CTP Office of Science lack the authority to exercise "best scientific practices" during their evaluation of PMTAs.


According to the commentary, disagreements in science are not fully suppressed, but are punished through various means of retaliation, such as lack of access to tasks, projects, and other opportunities needed for professional development and progression. In some departments, such as non-clinical science departments, employees are forced to adopt a "must accept" mentality by the leadership, which does not support reviewers in fulfilling their basic duty of providing impartial reviews using the best available science.


According to reports, many comments from staff members of the Food and Drug Administration (FDA) on the performance evaluation of the FDA Center for Tobacco Products (CTP) stated that the regulatory agency is in a state of confusion and is being influenced by external forces rather than scientific research.


In July, the FDA commissioned an independent review of its regulatory practices for food and tobacco, following several months of criticism over its handling of infant formula shortages and e-cigarette reviews. FDA Commissioner Robert Califf selected the non-profit Reagan-Udall Foundation, a non-governmental research group created by Congress to support the FDA's work.


This comment is anonymous and open to the public. Many of the comments depict an incompetent organization whose decisions are swayed by political agenda rather than based on science surrounding the next generation of nicotine products. According to reports, an FDA staff member claims that there is a toxic culture that permeates through the operating system, starting from the leadership team at the FDA.


The commentator wrote, "So-called leaders are not seeking feedback from actual reviewers, but only listening to a few of the loudest voices, who are not experts in any specific field." "Bias and nepotism, unconscious prejudices, racism and sexism, have permeated the entire office and department, and suggestions and feedback from minority groups and women have been ignored, even though they are the ones doing the most work.


Another critique suggests that arbitrary external pressures and politically-driven timelines (such as those imposed by judges) are driving the review process, rather than allowing for a thorough scientific examination. "When errors are found, CTP reviewers are blamed, when in fact there was not enough time allowed for a complete review. Staff are exhausted, constantly told to do more in less time, and blamed for not meeting crazy deadlines," the comment points out. "In cases where the review is completed and a scientific decision is made, they are also overruled by political agendas and forced to change their decision.


Another comment noted that the Tobacco Control Act (TCA) favors combustible tobacco products, allowing new combustible products to enter the market through easier pathways, such as being deemed substantially equivalent (SE) to existing tobacco products.


The CTP has stated that it supports the concept of risk continuum, where combustible products are the most harmful, while non-combustible products may appear safer in name only. However, the CTP has chosen to conduct individual pre-market reviews for new tobacco products," the commentary noted. "Therefore, any innovative products, such as e-cigarettes, will likely have to go through more robust and burdensome market pathways, such as e-cigarette PMTA.


However, it's not all doom and gloom, as some people claim that institution staff are simply overworked. A commentator stated that CTP has been working on impossible deadlines, dealing with a long queue of reviews, something that other FDA-regulated centers don't have to endure.


In comparison, the number of applications and products that it oversees is astronomical, yet we have received no protection, support, or leeway to deal with this burden," the comment stated. "Instead, it seems as though the CTP and OS are being blamed for queuing and not completing tasks on time, without anyone taking a look at how much work is being done to ensure completion as quickly as possible. As for queues and schedules, treating this center like any other is not helpful and only reinforces fatigue.


Another commentator pointed out that the FDA does not have the ability to conduct a "fair and equal" review of all PMTAs, a claim that the agency has denied in court cases surrounding its release of marketing refusals. "There are many layers to ensure that science is meaningful and communicated in a meaningful way. But there is no room for human error or breathing space to apply the system equitably to every application," the commentator noted. "Due to unreasonable deadlines, a lack of protection for personnel outside of CTP, and a shortage of personnel, we are all certainly overworked and stretched thin.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The translation of this article is solely intended for industry discussion and research purposes.


Due to limitations in the translator's proficiency, the translated article may not fully convey the original meaning. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, cross-border with Hong Kong, Macao or Taiwan, or international statements and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
German prosecutors and customs authorities are conducting a criminal investigation into an alleged cross-border organised vape network. Authorities say that between January 2024 and March 2025, four employees of an unnamed Chinese e-cigarette manufacturer allegedly built a network of sales agents and wholesalers that brought more than 7.6 million nicotine disposable vapes into Germany, causing an estimated €33.3 million in excise-tax losses. The manufacturer has not been named. Some products visible in enforcement images have packaging resembling products from FUMOT’s portfolio. European regulatory records from 2024, FUMOT’s public overseas-sales materials and records involving German vape importer and distribution company Zamu-Pro GmbH also show FUMOT/RandM products and German distribution activity during the period covered by the investigation.
Sep.21
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10